FDA grants Fast Track designation to Phanes’ spevatamig for first-line metastatic pancreatic cancer

The designation broadens regulatory support for the CLDN18.2 × CD47 bispecific antibody as Phanes advances its chemotherapy combination through Phase II development in metastatic pancreatic ductal adenocarcinoma.

The US Food and Drug Administration (FDA) has granted Fast Track designation to Phanes Therapeutics’ spevatamig (PT886) in combination with chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma (PDAC).

The designation provides opportunities for increased FDA interaction as Phanes advances the Phase II TWINPEAK programme, but does not constitute approval or establish clinical benefit.

Field	Content
Alert Type	Industry Update
Topic	FDA Fast Track designation; clinical development
Organisation(s)	Phanes Therapeutics; US Food and Drug Administration (FDA)
Affected Stakeholders	Pancreatic cancer researchers; oncologists; clinical investigators; patients with metastatic pancreatic ductal adenocarcinoma
Therapy Area(s)	Oncology; Pancreatic cancer
Geography	United States
What Happened	The FDA has granted Fast Track designation to spevatamig (PT886) in combination with chemotherapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma. Spevatamig is Phanes Therapeutics’ investigational bispecific antibody targeting CLDN18.2 and CD47 and is being evaluated in the Phase I/II TWINPEAK study. The new designation follows an earlier Fast Track designation covering metastatic CLDN18.2-positive pancreatic adenocarcinoma and supports increased regulatory interaction as the broader first-line programme progresses. Fast Track designation does not represent FDA approval.
Why It Matters	Metastatic PDAC remains associated with limited treatment options and poor outcomes, creating a need for additional first-line approaches. The designation is relevant because Phanes is evaluating spevatamig with chemotherapy across a broader metastatic PDAC population, rather than limiting development to patients selected as CLDN18.2-positive, although efficacy and safety still require confirmation in prospective trials.
Supporting Context	Spevatamig is a native IgG-like bispecific antibody designed to target CLDN18.2 and CD47 simultaneously. Phanes has reported early Phase II findings from the first-line metastatic PDAC programme, but these results come from relatively small patient cohorts and require confirmation in the larger study population.
Who Is Most Affected	Phanes and investigators developing spevatamig are most directly affected because Fast Track status provides opportunities for more frequent FDA interaction as the programme advances. Patients with metastatic PDAC are the relevant clinical population, although spevatamig remains investigational and is not currently an approved treatment.
Industry Impact	The designation supports continued development of a bispecific immunotherapy approach combining CLDN18.2 tumour targeting with CD47 blockade in pancreatic cancer. Its significance for the treatment landscape will depend on whether the Phase II programme confirms the efficacy and safety signals observed in earlier cohorts.
Key Takeaway	Fast Track designation gives Phanes additional regulatory interaction as it evaluates whether spevatamig plus chemotherapy can progress towards pivotal development in first-line metastatic PDAC.
What to Watch	Phanes expects topline Phase II results by the end of 2026, which will be important in determining whether the programme can progress towards Phase III development.
Primary Source	Phanes Therapeutics
Relevant Date	17 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com